Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has initiated a Phase I clinical trial of SGN-70, a humanized monoclonal antibody targeting CD70 that is being developed as an investigational therapy for autoimmune diseases.
Subscribe to our email newsletter
The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers. The Phase I study is a dose-escalation trial in which cohorts of healthy volunteers will receive single doses of SGN-70.
The clinical trial will be conducted in Switzerland and is expected to accrue approximately 60 volunteers.
According to the company, the CD70 antigen is highly expressed on activated T- and B-cells but not resting lymphocytes, and has been associated with a variety of autoimmune and inflammatory disorders.